Pages that link to "Q40393306"

The following pages link to Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. (Q40393306):

Displaying 24 items.

• Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. (Q27005950) (← links)
• The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis (Q27324363) (← links)
• Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. (Q30474047) (← links)
• Regional differences of the mouse brain in response to an α-linolenic acid-restricted diet: Neurotrophin content and protein kinase activity (Q30484661) (← links)
• Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease (Q33265508) (← links)
• Altered cholesterol and fatty acid metabolism in Huntington disease (Q34080706) (← links)
• Differential Changes in Postsynaptic Density Proteins in Postmortem Huntington's Disease and Parkinson's Disease Human Brains (Q35623502) (← links)
• Tardive dyskinesia and essential fatty acids (Q36508056) (← links)
• Update on Huntington's disease (Q36527807) (← links)
• Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. (Q37003956) (← links)
• Neurological benefits of omega-3 fatty acids (Q37187559) (← links)
• Emerging drug therapies in Huntington's disease (Q37488273) (← links)
• Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines (Q37580731) (← links)
• Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease (Q37776087) (← links)
• Huntington's disease: can mice lead the way to treatment? (Q37840353) (← links)
• Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice. (Q37866383) (← links)
• Animal models of Huntington's disease for translation to the clinic: best practices (Q38248687) (← links)
• Mouse models of Huntington disease: variations on a theme. (Q42155772) (← links)
• Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. (Q45290323) (← links)
• Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice (Q45306356) (← links)
• Are immunotherapies for Huntington's disease a realistic option? (Q52682390) (← links)
• Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. (Q55438236) (← links)
• New directions in therapeutics for Huntington disease. (Q64899737) (← links)
• Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis (Q92485095) (← links)